Category: IRDiRC

CDMRP: FY24 Research Funding Opportunities

The Congressionally Directed Medical Research Programs (CDMRP) announces new FY24 Research Funding Opportunities spanning the research spectrum from mechanistic research to clinical trials and that are now available in Rare Disease research areas. More information: https://cdmrp.health.mil/funding/default. All organizations, institutions and companies, both international and domestic, are encouraged to apply.

Read More

IRDiRC at World Orphan Drug Congress USA

Just less than a month until the World Orphan Drug Congress in Boston! We are delighted to announce that IRDiRC is a proud partner and exhibitor at the World Orphan Drug Congress USA, taking place on April 23-25, 2024 in Boston (MA, USA). Don’t miss out IRDiRC Chair, Dr. David Pearce’s presentation of the “International […]

Read More

Global Genes – RARE Drug Development Symposium

Just less than a month from the start of the RARE Drug Development Symposium, an event co-hosted by Global Genes and Orphan Disease Center of the University of Pennsylvania. The Symposium equips advocates with the knowledge, skills and connections they need to advance therapy development for their communities. This year’s theme is Innovative Ideas from […]

Read More

Foundation for Rare Diseases (France) shares call for projects

The Foundation for Rare Diseases (France) has launched a series of calls for proposals: Call for projects with ASL-HSP – “Research on hereditary spastic paraplegia”; Joint call for proposals with AFAF – “Research on Friedreich’s ataxia”; Call for projects – “Human and Social Sciences & Rare Diseases”; Call for projects with Vaincre La Mucoviscidose – […]

Read More

Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional

The US Food and Drug Administration (FDA) published a new grant call, on Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional. The purpose of this notice of funding opportunity (NOFO) is to address topics related to the use of digital health technologies (DHTs) for […]

Read More

Rare disease network to help solve the health system’s hardest cases (PRESS RELEASE)

A new network of Western Australian and international rare disease experts is being formed to develop precision medicines for the trickiest – and sometimes undiagnosed – cases across our hospital system. Affecting around 500,000 children in Australia, rare diseases are the biggest killer of children in developed countries with 95% of the approximately 7,000 known rare […]

Read More

Nominations open for ORDI Rare Star Awards

As the DNA Day is approaching on April 25th, to celebrate the 10th year anniversary of the Organization for Rare Diseases India (ORDI), an inaugural “ORDI Rare Star Awards” will be launched. These awards aim to honor and celebrate individuals who have made outstanding contributions in various categories related to rare diseases. Take some time to […]

Read More

Join the 9th Annual RARE Drug Development Symposium!

The RARE Drug Development Symposium, hosted by Global Genes and the Orphan Disease Center of the University of Pennsylvania, equips advocates with the knowledge, skills and connections they need to advance therapy development for their communities. This year’s theme is Innovative Ideas from Next Generation Change-Makers.The Symposium is planned to take place on April 29th-May […]

Read More

IRDiRC Nomination Call – Regulatory Scientific Committee (RSC)

The International Rare Diseases Research Consortium’s (IRDiRC) Regulatory Scientific Committee (RSC) has two openings for new members who are from the following regions: Africa, Australasia or South America. Apply before April 30, 2024. IRDiRC has 4 Scientific Committees, one each for the Diagnostics, Therapies, Interdisciplinary, and Regulatory aspects of rare diseases research. The Regulatory Scientific […]

Read More

FDA: Call for applications for the Rare Neurodegenerative Disease Grants Program

The U.S. Food and Drug Administration (FDA) announces a new funding opportunity on “Natural History, Clinical Outcome Assessment, and Biomarker Studies of Rare Neurodegenerative Diseases (U01) Clinical Trials Optional”. The purpose of this funding opportunity announcement (FOA) is to support efficient natural history studies alone or in conjunction with the development and validation of clinical […]

Read More